# CJC-1295 Ipamorelin FAQ: Direct Answers, Cited

> CJC-1295 Ipamorelin questions answered directly and cited: does it work, how it works, side effects, comparisons to sermorelin and tesamorelin, FDA status, and handling.

Direct answers to what people actually search, each cited where it makes a number claim.

## Does CJC-1295 / Ipamorelin work?

In the sense of raising growth hormone, yes — and it is measured. A single subcutaneous dose of CJC-1295 (DAC) raised mean plasma GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. "Works" for downstream body-composition goals in humans is extrapolated, not proven for the blend.

## How does CJC-1295 / Ipamorelin work?

Two switches on the same pituitary cells. CJC-1295 binds the GHRH receptor (raising cAMP) and ipamorelin binds the ghrelin receptor, GHS-R1a (raising calcium) — independent pathways [2][5]. Co-activating both produced roughly twice the cAMP of GHRH alone in transfected cells [4], so the combined GH pulse is larger than either arm's alone [3].

## Can you take both Sermorelin and Ipamorelin together?

Mechanistically they are the two complementary arms of a synergy stack — sermorelin is a GHRH analogue, ipamorelin a GHRP. In normal men, submaximal GHRP doses (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) stimulated GH release synergistically through independent mechanisms [3]. That said, no controlled trial has tested this specific fixed combination, and nothing here is dosing guidance.

## Can you take CJC-1295 / Ipamorelin and Tesamorelin together?

Tesamorelin is itself a GHRH analogue, so combining it with CJC-1295 (also a GHRH analogue) would double the same arm rather than add a complementary one. The studied synergy is GHRP + GHRH: submaximal GHRP plus GHRH stimulated GH release synergistically via independent mechanisms [3]. No trial has tested a tesamorelin + CJC-1295/ipamorelin combination, and this is not a protocol.

## Can you take CJC-1295 / Ipamorelin and Sermorelin together?

Sermorelin and the CJC-1295 half are both GHRH analogues — stacking them stacks the same arm. The synergy that the literature supports is between a GHRH analogue and a GHRP (ipamorelin): in normal men, GHRP plus GHRH produced supra-additive GH release through independent mechanisms [3]. No controlled study has evaluated this exact combination; nothing here is dosing advice.

## Does CJC-1295 / Ipamorelin increase testosterone?

The studied effect is on growth hormone and IGF-1, not testosterone. A single CJC-1295 (DAC) dose raised GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults [1]. The published literature on this stack does not demonstrate a direct increase in testosterone; claims to that effect are not supported by the cited data.

## What is CJC-1295 / Ipamorelin good for?

In research terms, it is studied as a way to raise the body's own growth-hormone output via two complementary receptors. The measured outcome is GH and IGF-1 elevation: 2- to 10-fold GH and 1.5- to 3-fold IGF-1 from a single CJC-1295 dose [1]. Reported downstream effects (sleep, recovery, body composition) are anecdotal for the combination — see [the effects page](/effects).

## What are the bad side effects of CJC-1295 and Ipamorelin?

Ipamorelin's defining trait is that it is *selective*: unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol above GHRH-stimulated levels even at doses over 200× the GH-releasing dose [2]. Across the GHS class, the chief concern is increased blood glucose from reduced insulin sensitivity [6]. Community-reported effects include water retention, injection-site reactions, flushing, and tingling — anecdotal, on [the effects page](/effects).

## How long do CJC-1295 and Ipamorelin take to work?

On the hormone level, fast: ipamorelin's peak GH response is around 40 minutes post-dose, and a single CJC-1295 (DAC) dose raised GH for six or more days and IGF-1 for 9–11 days [1]. On the experiential level, community reports of sleep and recovery changes are described within one to two weeks and body-composition shifts from around week five — anecdotal, not clinical, and not proven for the blend.

## How many mg of CJC-1295 and Ipamorelin should I take?

This site does not provide a human dose, and no validated human dose for the combination exists. Published research used CJC-1295 at 30–90 µg/kg subcutaneous in healthy adults [1] and ipamorelin at various rodent doses (e.g. 100 µg/kg three times daily) [2] — reported strictly as study data for which species and route, never as a recommendation to follow.

## Does CJC-1295 raise testosterone?

CJC-1295 is a GHRH analogue; its measured action is on growth hormone and IGF-1, not testosterone. A single subcutaneous dose raised GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults [1]. The cited literature does not establish a direct effect on testosterone.

## Does Ipamorelin reduce belly fat?

No human trial of ipamorelin or this stack shows that. The closest evidence is for a different GHRH analogue: a 2026 meta-analysis of tesamorelin found significant reductions in visceral adipose tissue (−27.71 cm²) and hepatic fat (−4.28%) [7]. Notably, ipamorelin showed a GH-independent *adipogenic* (fat-promoting) effect in GH-intact mice, which complicates a simple fat-loss story.

## What are the downsides to CJC-1295 / Ipamorelin?

Beyond the reported nuisances (water retention, injection-site reactions, flushing), the real downsides are evidential: neither component is FDA-approved, the fixed blend has never been tested in a controlled trial, and the chief class metabolic concern is raised blood glucose from reduced insulin sensitivity [6]. Elevating GH/IGF-1 also carries a theoretical oncologic concern, since IGF-1 is proliferative [1].

## Which is better, Sermorelin or Ipamorelin?

They are not interchangeable, so "better" depends on the role. Sermorelin is a GHRH analogue (the same arm as CJC-1295); ipamorelin is a selective GHRP working a different receptor [2]. They are complementary, not competing — the synergy that raises GH most is a GHRH analogue *plus* a GHRP combined [3], which is exactly what this stack is.

## Is Tesamorelin better than Ipamorelin?

Tesamorelin has far stronger human outcome data — a 2026 meta-analysis of 5 RCTs found significant visceral-fat (−27.71 cm²) and hepatic-fat (−4.28%) reduction with no serious adverse events [7] — but it is a GHRH analogue, a different mechanism from the GHRP ipamorelin. They are not the same class, and ipamorelin has no comparable controlled human efficacy trial.

## Is Ipamorelin stronger than Sermorelin?

"Stronger" is hard to compare across mechanisms — ipamorelin (a GHRP) and sermorelin (a GHRH analogue) act on different receptors. Ipamorelin matched GHRP-6's GH efficacy in swine while being selective enough to spare the cortisol axis even above 200× the GH-releasing dose [2]. The point of the stack is that a GHRP and a GHRH analogue combined exceed either alone [3].

## Which is safer, Sermorelin or Ipamorelin?

Neither has a controlled long-term human safety database, so a clean ranking is not available. Ipamorelin's notable safety feature is selectivity: it did not raise ACTH or cortisol above GHRH-stimulated levels even at very high doses [2]. Across the secretagogue class, the shared metabolic concern is raised blood glucose from reduced insulin sensitivity [6], and long-term cancer/mortality data are still needed.

## Is Ipamorelin stronger than Sermorelin or comparable to it?

Because they hit different receptors, the useful answer is mechanistic, not a single ranking: ipamorelin (GHRP) and sermorelin (GHRH analogue) are complementary arms. Ipamorelin matched older GHRP GH efficacy while sparing the cortisol axis [2]; the maximal GH response in the literature comes from combining a GHRH analogue with a GHRP, not from either alone [3].

## What is CJC-1295 / Ipamorelin?

A research combination of two peptides: CJC-1295, a long-acting GHRH analogue, and ipamorelin, a selective ghrelin-receptor GHRP. Together they are a growth-hormone-secretagogue "stack" — they prompt the pituitary to release more of the body's own GH via two independent receptors [2][5]. Neither is FDA-approved, and the fixed blend has never been tested in a controlled trial.

## How much CJC-1295 / Ipamorelin should I take?

There is no human dose provided here and no validated human dose for the combination. The published research used CJC-1295 at 30–90 µg/kg subcutaneous in healthy adults [1]; ipamorelin doses come almost entirely from rodent models [2]. These are reported as study data for documentation — which species, which route — never as instructions.

## Is CJC-1295 / Ipamorelin safe?

There is no controlled human safety trial of the combination, so "safe" cannot be asserted. Ipamorelin's class-favorable feature is selectivity — no rise in ACTH/cortisol above GHRH-stimulated levels even above 200× the GH-releasing dose [2]. The class review calls these compounds generally well tolerated short-term but flags raised blood glucose and missing long-term data [6].

## Is Ipamorelin FDA approved?

No. Neither ipamorelin nor CJC-1295 is FDA-approved for any indication; both are sold only as research chemicals. A GH-secretagogue review found the class well tolerated overall, with the chief concern being increased blood glucose from decreased insulin sensitivity and long-term cancer/mortality data still needed [6]. Both are also WADA-prohibited at all times under Section S2.

## How to reconstitute CJC-1295 / Ipamorelin (5mg)?

In laboratory-handling terms only: lyophilised peptide is reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol), then kept refrigerated at 2–8 °C, avoiding agitation and repeated freeze-thaw, since aqueous peptide degrades over weeks via deamidation. This describes the documented stability profile — not an administration instruction, and no human use is endorsed.

---

Two receptors logged on one onyx panel — the supra-additive GH crest read off single-peptide data and the general synergy work, the fixed blend's missing trial left as an empty cell; no clinic behind the console and nothing here dosed, stacked, or sold.